Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bristol-Myers Squibb Co before investing.

In this article, we go over a few key elements for understanding Bristol-Myers Squibb Co’s stock price such as:

• Bristol-Myers Squibb Co’s current stock price and volume
• Why Bristol-Myers Squibb Co’s stock price changed recently
• Upgrades and downgrades for BMY from analysts
• BMY’s stock price momentum as measured by its relative strength

About Bristol-Myers Squibb Co (BMY)

Before we jump into Bristol-Myers Squibb Co’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Want to learn more about Bristol-Myers Squibb Co’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co’s Stock Price as of Market Close

As of October 26, 2023, 4:00 PM, CST, Bristol-Myers Squibb Co’s stock price was $52.97.

Bristol-Myers Squibb Co is down 6.43% from its previous closing price of $56.61.

During the last market session, Bristol-Myers Squibb Co’s stock traded between $55.96 and $56.77. Currently, there are 2,093.00 million shares of Bristol-Myers Squibb Co stock available for purchase.

Bristol-Myers Squibb Co’s price-earnings (P/E) ratio is currently at 15.1, which is low compared to the Pharmaceuticals industry median of 17.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Bristol-Myers Squibb Co Stock Price History

Bristol-Myers Squibb Co’s (BMY) price is currently down 8.74% so far this month.

During the month of October, Bristol-Myers Squibb Co’s stock price has reached a high of $58.06 and a low of $52.92.

Over the last year, Bristol-Myers Squibb Co has hit prices as high as $81.44 and as low as $55.70. Year to date, Bristol-Myers Squibb Co’s stock is down 15.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bristol-Myers Squibb Co Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 25, 2023, there were 12 analysts who downgraded Bristol-Myers Squibb Co’s stock and 3 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Bristol-Myers Squibb Co’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bristol-Myers Squibb Co’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bristol-Myers Squibb Co’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bristol-Myers Squibb Co (BMY) by visiting AAII Stock Evaluator.

Relative Price Strength of Bristol-Myers Squibb Co

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 25, 2023, Bristol-Myers Squibb Co has a weighted four-quarter relative price strength of -5.99%, which translates to a Momentum Score of 46 and is considered to be Average.

Want to learn more about how Bristol-Myers Squibb Co is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bristol-Myers Squibb Co Stock Price: Bottom Line

As of October 26, 2023, Bristol-Myers Squibb Co’s stock price is $52.97, which is down 6.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bristol-Myers Squibb Co stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.